A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in african american and hispanic american patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy

Clinical Therapeutics

Volumn 29, Issue 9, 2007, Pages 1900-1914

  Davidson, Jaime A ^a   McMorn, Stephen O ^b   Waterhouse, Brian R ^b   Cobitz, Alexander R ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

African American; glyburide; Hispanic American; rosiglitazone; type 2 diabetes

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; FIBRINOGEN; GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; GLYCOTROL XL; HEMOGLOBIN A1C; INSULIN; PHOSPHOLIPASE A2; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SULFONYLUREA; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADD ON THERAPY; ADULT; AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ETHNICITY; FEMALE; GLUCOSE HOMEOSTASIS; HISPANIC; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

AFRICAN AMERICANS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GLYBURIDE; HISPANIC AMERICANS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 36749073818     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.09.011     Document Type: Article

References (53)

1. Cowie C., Rust K., Byrd-Holt D., et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 29 (2006) 1263-1268
2. Tull E., and Roseman J. Diabetes in African-Americans. Diabetes in America (2002), National Institutes of Health/National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, Md 613-630
3. Stern M., and Mitchell B. Diabetes in Hispanic-Americans. Diabetes in America (2002), National Institutes of Health/National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, Md 631-659
4. Cossrow N., and Falkner B. Race/ethnic issues in obesity and obesity-related comorbidities. J Clin Endocrinol Metab. 89 (2004) 2590-2594
5. Bonds D., Zaccaro D., Karter A., et al. Ethnic and racial differences in diabetes care: The Insulin Resistance Atherosclerosis Study. Diabetes Care 26 (2003) 1040-1046
6. Shenolikar R., Balkrishnan R., Camacho F., et al. Race and medication adherence in Medicaid enrollees with type-2 diabetes. J Nat/Med Assoc. 98 (2006) 1071-1077
7. The UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). [published correction appears in Lancet. 1999;354:602]. Lancet. 352 (1998) 837-853
8. American Diabetes Association. Standards of medical care in diabetes-2006. [published correction appears in Diabetes Care. 2006;29:1192]. Diabetes Care. 29 Suppl 1 (2006) S4-S42
9. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management-2002 update. Endocr Pract. 8 (2002) 43-84
10. Davidson J., Blonde L., Jellinger P., et al. Road map for the prevention and treatment of type 2 diabetes. Endocr Pract 12 Suppl 1 (2006) 148-152
11. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med. 16 (1999) 716-730
12. Brown A., Gerzoff R., Karter A., et al., TRIAD Study Group. Health behaviors and quality of care among Latinos with diabetes in managed care. Am J Public Health. 93 (2003) 1694-1698
13. de Rekeneire N., Rooks R., Simonsick E., et al., Health, Aging and Body Composition Study. Racial differences in glycemic control in a well-functioning older diabetic population: Findings from the Health, Aging and Body Composition Study. [published correction appears in Diabetes Care. 2003;26:3368]. Diabetes Care. 26 (2003) 1986-1992
14. Gary T., McGuire M., McCauley J., and Brancati F. Racial comparisons of health care and glycemic control for African American and white diabetic adults in an urban managed care organization. Dis Manag 7 (2004) 25-34
15. Chiu K., Cohan P., Lee N., and Chuang L. Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function. Diabetes Care 23 (2000) 1353-1358
16. Haffner S., D'Agostino R., Saad M., et al. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes 45 (1996) 742-748
17. Saad M., Lillioja S., Nyomba B., et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med. 324 (1991) 733-739
18. Avandia [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; Available at:. http://us.gsk.com/products/assets/usavandia.pdf Accessed August 10, 2007
19. Jucker B., Schaeffer T., Haimbach R., et al. Normalization of skeletal muscle glycogen synthesis and glycolysis?in rosiglitazone-treated Zucker fatty rats: An in vivo nuclear magnetic resonance study. Diabetes 51 (2002) 2066-2073
20. Lebovitz H., Dole J., Patwardhan R., et al., Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. [published correction appears in J Clin Endocrinol Metab. 2001;86:1659]. J Clin Endocrinol Metab. 86 (2001) 280-288
21. Wolffenbuttel B., Gomis R., Squatrito S., et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 17 (2000) 40-47
22. Fonseca V., Rosenstock J., Patwardhan R., and Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. [published correction appears in JAMA. 2000;284:1384]. JAMA. 283 (2000) 1695-1702
23. Osei K., Gaillard T., Kaplow J., et al. Effects of rosiglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism 53 (2004) 1552-1557
24. Glucotrol XL (glipizide) [prescribing information] [Pfizer Web site]. Available at:. http://www.pfizer.com/pfizer/download/uspi_glucotrol_xl.pdf Accessed August 10, 2007
25. Dialβeta (glyburide) [prescribing information] [sanofi-aventis Web site]. Available at:. http://products.sanofiaventis.us/diabeta/diabeta.pdf Accessed August 10, 2007
26. Micronase (glyburide) [prescribing information] [Pfizer Web site]. Available at:. http://www.pfizer.com/products/rx_product_micronase.jsp Accessed August 10, 2007
27. Glynase [prescribing information] [Pfizer Web site]. Available at:. http://www.pfizer.com/products/rx_product_glynase.jsp Accessed August 10, 2007
28. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH Guidelines for Good Clinical Practice. Available at:. http://www.ich.org/ Accessed March 3, 2006
29. World Medical Association. World Medical Association Declaration of Helsinki. Available at:. http://www.wma.net/e/ethicsunit/helsinki.htm Accessed September 7, 2006
30. Schulman R. Statistics in Plain English with Computer Application (1992), Van Nostrand Reinhold, New York, NY
31. Walpole R., Myers R., and Myers S. Probability and Statistics for Engineers and Scientists. 6th ed. (1998), Prentice Hall, Saddle River, N J
32. Matthews D., Hosker J., Rudenski A., et al. Homeostasis model assessment: Insulin resistance and betacell function From fasting plasma glucose and insulin concentrations in man. Diabetologia. 28 (1985) 412-419
33. Levy J., Matthews D., and Hermans M. Correct homeostasis model assessment (I-IOMA) evaluation uses the computer program. Diabetes Care 21 (1998) 2191-2192
34. National Institute of Diabetes. National Diabetes Statistics fact sheet: General information and national estimates on diabetes in the United States, 2005 (2005), US Dept of Health and Human Services, National Institutes of Health, Bethesda, Md
35. Turner R., Cull C., Frighi V., Holman R., and UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonyfurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA. 281 (1999) 2005-2012
36. Kerenyi Z., Samer H., Yan Y., and Stewart M. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of gliben-clamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 63 (2004) 213-223
37. Del Prato S., Felton A., Munro N., et al. Global Partnership for Effective Diabetes Management. Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract. 59 (2005) 1345-1355
38. Carey D., Cowin G., Galloway G., et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. [published correction appears in Obes Res. 2002;10:following table of contents]. Obes Res. 10 (2002) 1008-1015
39. Mayerson A., Hundal R., Dufour S., et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51 (2002) 797-802
40. Mohanty P., Aljada A., Ghanim H., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89 (2004) 2728-2735
41. Drouet L. Atherothrombosis in diabetes-its evolution and management. Diabetes Obes Metab 1 Suppl 2 (1999) S37-S47
42. Plutzky J., Viberti G., and Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: Mechanistic links and therapeutic targets. J Diabetes Complications 16 (2002) 401-415
43. Yudkin J., Panahloo A., Stehouwer C., et al. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia 43 (2000) 1099-1106
44. Gregorio F., Ambrosi F., Manfrini S., et al. Poorly controlled elderly type 2 diabetic patients: The effects of increasing sulphonylurea dosages or adding metformin. DiabetMed 16 (1999) 1016-1024
45. Haffner S., Greenberg A., Weston W., et al. Effect of rosiglitazone treatment on nontraditional mark-?ers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
46. Sidhu J., Cowan D., and Kaski J. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coil Cardiol. 42 (2003) 1757-1763
47. Heine R. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II-"the cons.". Horm Metab Res. 28 (1996) 526-822
48. Nesto R., Bell D., Bonow R., et al., American Heart Association and the American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 108 (2003) 2941-2948
49. Jun J., Gong W., and Mathur R. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients. Am J Health Syst Pharm 60 (2003) 469-473
50. Tan M., Johns D., Gonzalez G., et al., GLAD Study Group. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. Clin Ther. 26 (2004) 680-693
51. King A., Armstrong D., and Chinnapongse S. Comparison of glycemic and lipid response to pioglitazone treatment in Mexican-Americans and non-Hispanic Caucasians with type 2 diabetes. Diabetes Care 26 (2003) 246-248
52. Buchanan T., Xiang A., Peters R., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 (2002) 2796-2803
53. Xiang A., Peters R., Kjos S., et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55 (2006) 517-522